Co-Authors
This is a "connection" page, showing publications co-authored by THOMAS CATE and WENDY KEITEL.
Connection Strength
0.703
-
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
Score: 0.089
-
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
Score: 0.087
-
Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
Score: 0.083
-
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
Score: 0.070
-
Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis. 2001 Jan 15; 183(2):329-332.
Score: 0.048
-
Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997 Aug; 176 Suppl 1:S38-44.
Score: 0.038
-
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
Score: 0.038
-
Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
Score: 0.036
-
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
Score: 0.031
-
Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993 Feb; 167(2):305-11.
Score: 0.028
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.025
-
Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis. 1990 Jan; 161(1):22-6.
Score: 0.023
-
Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
Score: 0.022
-
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29; 26(32):4057-61.
Score: 0.020
-
Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
Score: 0.020
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.019
-
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
Score: 0.018
-
Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
Score: 0.008